ACRS
Aclaris Therapeutics Inc
5.20$
-4.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.0% | 97.8% | 98.9% | 85.8% | 65.1% | 85.3% | 81.2% | 81.6% | 90.9% | 65.3% | 57.2% | 94.3% | |
| 61.9% | 10.5% | 17.1% | 85.8% | 20.7% | 36.6% | 31.2% | 10.9% | 17.8% | 20.2% | 11.2% | 12.4% | |
| 92.8% | 97.8% | 98.9% | 85.8% | 61.0% | 76.3% | 76.5% | 76.2% | 85.5% | 60.3% | 51.6% | 56.6% | |
| – | 0.0% | – | 0.2% | 0.2% | 0.7% | 1.1% | 0.2% | 0.2% | 0.2% | 0.1% | 3.5% | |
| – | 0.0% | 0.0% | -2.6% | 0.3% | 5.1% | – | -13.6% | -4.8% | – | – | – | |
| 3.0% | 0.4% | 0.3% | 0.9% | 0.8% | 7.3% | 2.3% | 0.5% | 0.4% | – | – | – | |
| – | 0.0% | 0.0% | 7.6% | 6.7% | 0.0% | – | – | – | – | – | – | |
| – | 0.0% | 0.0% | 3.0% | 26.5% | 7.3% | 10.1% | 2.8% | 2.7% | 0.1% | – | – | |
| 219.4% | 1.7% | 3.7% | 7.5% | 21.9% | 28.9% | 46.8% | 21.4% | 22.4% | 20.4% | 29.4% | 35.8% | |
| 8.4% | 1.7% | 3.5% | 5.2% | 9.9% | 22.8% | 21.0% | 9.1% | 8.6% | 15.7% | 14.3% | 17.9% | |
| – | – | – | 0.1% | 0.1% | 0.6% | 0.9% | 0.3% | 0.3% | 0.2% | 0.4% | 0.3% | |
| 7.3% | 0.9% | 1.6% | 3.2% | 4.2% | 10.1% | 7.4% | 4.0% | 4.1% | 4.5% | 2.1% | 8.2% | |
| – | 0.0% | 0.0% | 0.1% | 10.9% | – | 15.1% | – | – | – | – | – | |
| -119.4% | 98.3% | 96.3% | 92.5% | 78.1% | 71.1% | 53.2% | 78.6% | 77.6% | 79.6% | 70.6% | 64.2% | |
| -119.4% | -45.5% | -51.6% | -65.5% | -106.0% | -461.4% | -712.8% | -237.0% | -268.0% | -390.5% | -409.8% | -603.1% | |
| 61.3% | 19.8% | 12.2% | 11.5% | 11.9% | 42.0% | 60.1% | 22.6% | 25.6% | 35.4% | 35.1% | 76.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.